Afghanistan National Medicines Policy

2014 - 2019
This National Medicines Policy (NMP) is the overall policy document for the Afghanistan pharmaceutical sector. This policy constitutes part of continuous efforts by the Ministry of Public Health (MoPH) and the stakeholders to ensure the availability, accessibility, affordability and rational use of safe, efficacious and quality medicines. It aims to provide comprehensive pharmaceutical services as a major component of promoter, preventive, curative, rehabilitative and palliative services. It is also a commitment to building a responsive, sustainable and viable pharmaceutical industry.

The policy comprehensively covers medicines regulation, quality assurance, selection, supply and rational use. It states mechanisms to secure sustainable financing, build local human capacity for services and manufacture of essential and complementary medicines. Strategies for international cooperation and systems for monitoring and evaluating implementation have also been set out.

This edition of the NMP was developed through a systematic process as internationally established. A NMP Task Force (NMPTF) of key technical stakeholders was established under the direct supervision and leadership of the MoPH. The NMPTF consulted widely and reviewed the current pharmaceutical situation in Afghanistan. An initial draft policy document was developed and subjected to widespread consultation with stakeholders both internally and externally. The final draft document was compiled and presented to the MoPH, which took the final decision on all aspects of the policy and duly approved it for implementation.

Logically, this policy document will be followed by a National Pharmaceutical Master Plan (NPMP), which will set out strategies, objectives, activities and expected outcomes/outputs to implement all agreed components.

I am very optimistic that all stakeholders involved in the development of this policy will remain committed to it, and support Government efforts to fully implement it. It is also my hope that our development partners will find the policy a useful guide in providing technical and financial assistance in the pharmaceutical sector. Hopefully, in the next few years when we have implemented this policy, we can together rejoice over positive results of our combined efforts.

I wish to sincerely commend the Strengthening Pharmaceutical Systems (SPS) Project funded by the United States Agency for International Development and implemented by Management Sciences for Health for the tremendous technical support, I also thank the NMP Task Force members and all those who contributed to developing this policy document.

Dr. Suraya Dalil
Minister of Public Health

July 9, 2014
ACKNOWLEDGMENTS

This second edition of National Medicines Policy has naturally drawn upon, and been developed based on the outline, of the previous policy in accordance with changes and development in pharmaceutical sector. It has been drafted through a systematic process which provided consultative access to all concerned and involved stakeholder.

The development of this National Medical Policy began during Dr. Sohaila Seddiq’s tenure as Minister of Public Health. Formulating that policy has involved many staff members of the Ministry of Public Health (MoPH) at both central and provincial levels. Many Afghans and international stakeholders, donors. Stephanie Simmonds, the Department for International Development, United Kingdom-supported consultant have contributed to the policy’s development and played a key role in its implementation. We extend our sincere thanks to all.

Also sincere thanks for contribution of NMPTF, staff member of MoPH, MoHI, MoJ, MoE and GDP, National and international organizations, WHO, USAID, SPS and other donors which involved in revision of NMP 2014-2019 and will play the key role in its implementation.

The General Directorate of Pharmaceutical Affairs further expresses its gratitude to the Strengthening Pharmaceutical Systems (SPS) Project for the technical support, with the financial assistance of US Agency for International Development (USAID). Contributors who played oversight and consultancy roles in drafting of this policy

Pharmacist Abdul Hafiz Quraishi

General Director of Pharmaceutical Affairs

Jul. 09. 2014
The consistent efforts of the NMPTF members resulted in the development and finalization of this policy. They are:

- Professor Nadir Ahmad Exeer—Kabul Medical University (NMP Taskforce chairperson)
- Pharmacist Abdul Hafiz Quraishi—General Director of Pharmaceutical Affairs
- Pharmacist Abdul Khalil Khakzad—Director of Avicenna Pharmaceutical Institute
- Pharmacist Mohamad Junaid Nemati—Faculty of Pharmacy
- Mohammad Yusuf Joyan—Ministry of Higher Education
- Pharmacist Ayisha Norzaie—Ex director of General Directorate of Pharmaceutical Affairs
- Pharmacist Nazir Ahmad Ahmadzad—General Directorate of Pharmaceutical Affairs
- Pharmacist Mohammad Nazir Hiedarzad—General Directorate of Pharmaceutical Affairs
- Mrs. Nazifa Hashemi—Ministry of Justice
- Mr. Noorullah Adel—Ministry of Economics
- Dr. Sediqullah Reshteen—General Directorate of Policy and Planning
- Pharmacist Shakila Amarkhil—General Directorate of Pharmaceutical Affairs
- Pharmacist Fahima Habibi—General Directorate of Pharmaceutical Affairs
- Dr. S.Jawid Badakhsh—Ministry of counter Narcotics.
- Pharmacist Fida Mohamad Barin—Legislation Implementation Ensuring Directorate
- Alhaj. Mohammad Esmaiel Daqiq—Drug Seller Association, Kabul City
- Dr. Mir Omar Masoud Atefi—National Medicine Policy Revision Process Consultant
- Dr. Abdul Ghafar Amin—Afghanistan Doctors and Medical workers Association
- Elhaj Abdul Khaliq Zazai Watandoost—Afghanistan National Medicines Services Organization

The Task Force is expected to have a wide ranging composition and interaction can be made through any of the representatives.

The Task Force will consult widely with all active players. It is expected that series of workshops, surveys, and consultations will be held on each key aspect of its objectives.

The secretary to the Task Force will ensure that information on its operation is widely circulated and will probably be available through web sites and electronic media.

After its formal empowerment, the Task Force will announce the contact details and routes for both receiving inputs and disseminating information on its activities.

The organizations that were represented in the review process include—

- Ministry of Public Health
  - General Directorate of Pharmaceutical Affairs
- General Directorate of Administrative and Finance Affairs
- General Directorate of Health Services
- General Directorate of Policy and Planning
- Directorate of Monitoring and Evaluation
- Legislation Implementation and Ensuring Directorate
- National Medicines and Food Quality Control Laboratory
- Ministry of Counter Narcotics
- Ministry of Justice
- Ministry of Economy
- Ministry of Higher Education
  - Kabul Medical University
  - University of Kabul, Faculty of Pharmacy
  - Academic Affairs Coordination Directorate
- Afghan National Standards Authority
- Professional Associations
  - Pharmacy Association
  - Afghanistan Doctors and Medical Workers Association
  - Afghanistan National Medicines Services Organization
- United Nations organizations,
  - World Health Organization
  - UNICEF
  - UNFPA
- Donor Representatives
  - USAID
  - European Commission
  - World Bank
- Nongovernmental Organization Representatives
  - Ministry of Economy, Nongovernmental Organization Department
- Management Sciences for Health
  - Strengthening Pharmaceutical Systems
  - Tech – Serve
  - TB – Care
  - BASICS
- Health Partners International of Canada

Other colleagues and partners who cooperate in development of this policy as technical consultants and oversight bodies are:

- Mohammad Zafar Omari, SPS/Afghanistan Chief of Party
- Wahidullah Karwar, SPS Supply Chain Systems Senior Technical Advisor in Afghanistan
- Ahmad Farid Sarwary SPS Regulation/Legal officer in Afghanistan
- Mohammad Basir SPS Regulation/Legal officer in Afghanistan
- Noor Ahmad Zulal SPS Quality Assurance officer in Afghanistan
- Sediqa Hassani SPS Quality Assurance officer in Afghanistan
- Ahmad Jawid Ehsan SPS Supply Chain Planning Advisor in Afghanistan
- Alhaj Inua Yusuf, SPS Quality Assurance Consultant in Gana
• David Lee, Director for Technical Strategy and Quality, Center for Pharmaceutical Management in Arlington Washington
• Andy Barraclough, consultant, SPS in Thailand
• Luther Gwaza, SPS Regulatory Consultant in Zimbabwe
• Mark Morris, SPS Country Manager in Arlington Washington
• Shiou-Chu Judy Wang, SPS Senior Program Associate in Arlington Washington
• Niranjan Konduri, SPS consultant in Arlington Washington
• Terry Green, SPS Consultant in Arlington Washington
• Paul Ickx, Center for Health Services, MSH, TechServe in French
• Tana Wuliji, SPS Consultant in Australia
• Professor Graham Dukes NMP consultant in Sweden
ACRONYMS

AMR  antimicrobial resistance
DMAA Deputy Minister for Administrative Affairs
EML Essential Medicines List
FDA Food and Drug Administration
GDP Good Dispensing Practice
GDPA General Directorate for Pharmaceutical Affairs
GMP Good Manufacturing Practice
HRD Human Resource Development
INN International Nonproprietary Name
LML Licensed Medicines List
M&E Monitoring and Evaluation
MoPH Ministry of Public Health
MTC(DTC) Medicines and Therapeutics Committees
NMFB National Medicine and Food Board
NMP National Medicine Policy
NMPTF National Medicine Policy Task Force
NPMP National Pharmaceutical Master Plan
QA Quality Assurance
R&D Research and Development
RMU Rational Medicines Use
STG Standard Treatment Guideline
TRIPS Trade-Related Aspects of Intellectual Property Rights
USD United States dollar
WHO World Health Organization
CONTENTS

PREFACE .................................................................................................................................. ii

ACKNOWLEDGMENTS ....................................................................................................... iii

ACRONYMS ........................................................................................................................... vii

1. INTRODUCTION .............................................................................................................. 1
   1.1. Afghanistan National Health System .............................................................. 1
   1.2. Afghanistan Pharmaceutical Market .............................................................. 2
   1.3. MoPH Commitment to Strengthening the Pharmaceutical Sector ............... 4
   1.4. Afghanistan NMP 2014-2019 .......................................................................... 4

2. GOAL AND OBJECTIVES ............................................................................................... 6
   2.1. Goal .................................................................................................................. 6
   2.2. Objectives : ...................................................................................................... 6

3. KEY PRINCIPLES ............................................................................................................ 7

4. Good Governance .......................................................................................................... 7

5. REGULATION AND QUALITY ASSURANCE ............................................................. 9
   5.1. Regulation ......................................................................................................... 9
   5.2. Registration ..................................................................................................... 10
   5.3. Control and Inspection .................................................................................... 11
   5.4. Regulation of the Pharmaceutical Profession and Services ......................... 12
   5.5. Control of Premises and Providers ................................................................ 13
   5.6. Specific Quality Assurance Measures ............................................................ 13
   5.7. Adverse Reaction Monitoring (Pharmacovigilance) ....................................... 13

6. LOCAL MANUFACTURE ............................................................................................. 15
   6.1. Support the Local Manufacturing .................................................................. 15
   6.2. Traditional Medicines ..................................................................................... 16
   6.3. Production and Production Inspection ............................................................ 16

7. SELECTION .................................................................................................................... 17
   7.1. Licensed and Essential Medicines ................................................................. 17

8. SUPPLY ........................................................................................................................... 19
   8.1. Procurement .................................................................................................... 19
   8.2. Donations ......................................................................................................... 20
   8.3. Storage ............................................................................................................. 20
   8.4. Inventory Control and Monitoring of Supply ............................................... 21
   8.5. Distribution ...................................................................................................... 21

9. RATIONAL USE OF MEDICINES .............................................................................. 23
   9.1. Awareness, Education, Training, and Rational Use of Medicines ................. 23
   9.2. Information ....................................................................................................... 24
   9.3. Rational Prescribing ....................................................................................... 24
   9.4. Rational Dispensing ....................................................................................... 25
   9.5. Medicines and Therapeutics Committees ..................................................... 26
   9.6. Anti-microbial Resistance (AMR) .................................................................. 27

10. MEDICINES FOR NEW, EMERGING, AND RE-EMERGING DISEASES ............. 28
1. INTRODUCTION

1.1. Afghanistan National Health System

According to the National Health Policy and Strategy, Afghanistan is a post conflict country in the process of determining the nation’s political system. The national health policy was developed based upon the expressed core values of the Ministry of Public Health (MoPH), which re-enforces the strong perception of the MoPH as an institution working for reform. The Government’s Public Investment Program 2004 highlighted the need for “accelerated implementation through concerted and focused action.”

To safeguard the public and, in particular, to ensure quality of clinical services, the MoPH has been focusing on reviewing, developing, and enforcing relevant legal and regulatory instruments and policies that govern health and health-related work.

The vision of the MoPH is stated as “Better health for all Afghans in order to contribute to economic and social development,” and the mission statement is a commitment to ensuring the accelerated implementation of quality health care. The MoPH aims to achieve equitable, affordable, and sustainable quality support services, including those for pharmaceuticals. The provision of appropriate essential medicines at each level of the public health system is one of the seven core elements of the Basic Package of Health Services (BPHS) for Afghanistan.

1.1.1. National Medicines and Food Board

The National Medicines and Food Board is intended to serve as an advisory body for implementation of policy and monitoring the medicines regulatory authority general activities in relation to medicines and related products.

1.1.2. National Medicine Regulatory Authority

The General Directorate of Pharmaceutical Affairs (GDPA) is the only pharmaceutical regulatory body in the country. In order to provide better coordination and enforcement of NMP provisions, the GDPA will be promoted to an autonomous Medicines Regulatory Authority body and will be accountable to NMFB and ultimately to the minister of public health. Further when the independent Food and Drug Administration (FDA) according to National Health and Nutritional Policy 2012-2020, is to be formed and empowered through legislation and regulation and when the Food products regulation became operational, then the Medicines Regulatory Authority will become a part of FDA.

Until such time GDPA will continue to provide the functions of the National Medicines Regulatory Authority.

Vision of the General Directorate of Pharmaceutical Affaires (GDPA): All the country needs in terms of pharmaceutical and health products and also standard pharmaceutical services are met.

The GDPA mission is: to lead, initiate, and manage all programs and system relevant to pharmaceutical and to ensure that all pharmaceutical needs at the country level are met.

*Hospitals designated as Non-profit State-Owned enterprises as defined in the Hospital Sector Strategy of 2011 (see reference list).
The values of National Medicine Regulatory Authority are to be—

- Dedication to the country and national interests
- Equity and equality
- Honesty and competence
- Ensure and maintain Quality and transparency
- Equal access to quality medicines
- Availability of affordable medicines for the majority of the population
- Observance of professional standards

The working principles of National Medicine Regulatory Authority are to have—

- Respect, honesty, responsibility, transparency, and accountability for national benefit
- Evidence-based and with no conflict of interest in decision making for national benefit
- Effective and efficient equitable pharmaceutical services
- Respect and equitability when dealing with people and all stakeholders
- Quality, effective, safe, and affordable medicines to provide to the majority of the population
- Continuous efforts to improve the pharmaceutical sector so as to more effectively support the national health sector

1.2. Afghanistan Pharmaceutical Market

The world pharmaceutical market has been changing radically. There has been a massive increase in low cost generic pharmaceutical manufacturing in Asia. In contrast to the 1990s, the origin of medicines in use in most developing countries today is now far more likely to be from the Asian region. For Afghanistan, medicines origins are notably China, India, Iran, and Pakistan; none of which countries are regarded as having stringent regulatory (medicines) authorities (SRAs).

In essence, any medicine from a SRA country can automatically be considered to have been adequately quality controlled to internationally accepted standards. Medicines from non-SRA countries are not automatically qualified but companies from non-SRA countries can still receive individual medicine approval from the World Health Organization (WHO) prequalification, the Global Fund to Fight Aids, Tuberculosis and Malaria (Global Fund), and US Food and Drug Administration provisional registration schemes. However, for a recipient country to ensure an adequately quality assured medicine, a detailed knowledge of the schemes and the individual approvals is required. The Global Fund and numerous other donors require all medicines they fund to be procured from either a SRA country and/or to have received an individual certification from one of the recognized prequalification or registration schemes.

The upshot of this situation is that it is now more difficult to control the quality of imported medicines, and greater regulatory oversight is necessary.

There has been a world-wide increase in the counterfeiting of medicines. WHO estimates that some 10 percent of medicine on the world market is counterfeit and that in developing countries the percentage of counterfeit medicines is 25 percent.

In the current world pharmaceutical situation there is clearly a need for a strengthened policy
and regulatory environment to help to protect against counterfeit medicines.

Currently, the total Afghanistan government and per capita expenditure for the pharmaceutical sector are not reliably known. The same is true for the total value of domestic pharmaceutical production and imports and exports of active pharmaceutical ingredients and finished pharmaceutical products. This is attributed to the lack of a database or credible source for collecting this information.

However, the GDPA of MoPH estimates that annually the private-for-profit and private not-for-profit nongovernmental organizations (NGOs) sectors hold medicines worth is totally about 111 million dollars (USD) based on GDPA official report. Other sources estimate that the private-for-profit sector accounts for between 70 and 80 percent of total pharmaceutical consumption and that the annual market may be worth up to two fold of it.
1.3. MoPH Commitment to Strengthening the Pharmaceutical Sector

The MoPH has the responsibility to ensure that medicines being distributed in the country are safe, effective, and of standard quality. This responsibility is in accordance with the concept of pharmaceutical management support defined in the Afghanistan National Development Strategy. For some time now, the MoPH has demonstrated a strong commitment to strengthening the pharmaceutical sector. For example, the ministry has continuously supported the pharmaceutical and laboratory services despite its budgetary challenges and the recent Health and Nutritional Policy 2012-2020 specifically mentions enhance capacity in regulating the pharmaceutical sector through different mechanisms of quality assurance. Furthermore, various task forces, including the National Medicines Policy Task Force (NMPTF), were established at the national level to lead the development of appropriate strategies for medicines quality assurance (QA) for the country.

As stated in the National Health Policy and Strategy, the increasingly pro-active leadership of the MoPH has resulted in its being widely considered one of the most progressive and reform-minded Afghan ministries. It has acquired the trust of other Afghan ministries, international donors, multilateral agencies, and nongovernmental organizations. The MoPH is committed to establishing and using standard international level procurement, stocking, and logistics systems to enable international contracting, bidding, and stocking.

To this end the MOPH has recently re-launched the National Medicines and Food Board (NMFB) to serve the policy advisory and monitoring roles for the related regulatory authority on medicines and related products related matters.

In order to ensure effective implementation of medicines regulatory authority in the country the MOPH will empower the GDPA to form an autonomous, competent and authorized medicines regulatory authority accountable to the NMFB and ultimately to the minister of public health through appropriate legislation and regulation to act as the prime implementing body for all medicines regulatory activities. And will be committed to further improve it as a part of autonomous Food and Drug Administration.

1.4. Afghanistan NMP 2014-2019

The 2003 Afghanistan National Medicines Policy (NMP) document represented a major achievement in establishing basic policies at that time. However, since then the pharmaceutical sector activities in the country have grown, and the policy is no longer considered adequate for the new challenges and opportunities, both locally and internationally.

A NMP is a commitment to a goal and a guide for action. The policy expresses and prioritizes the short-, medium-, and long-term goals set by the government for the pharmaceutical sector and identify the main strategies for attaining them. It provides a framework within which the activities of the pharmaceutical sector can be coordinated. It covers both the public and private sectors, and involves all the main stakeholders in the pharmaceutical sector.

A well prepared NMP, presented and printed as an official government statement, is important because it acts as a formal record of aims, decisions, expected outcomes, and commitments. Without a formal policy document there may be no general overview of what is needed. As a result, some government measures may conflict with others because the
various goals and responsibilities are not clearly defined and understood.

This policy document was developed through a systematic process of consultation with all major stakeholders in both the public and private pharmaceutical sectors. The groups involved defined and agreed upon the goal and objectives, set priorities, developed strategies, and commitment made based on available and anticipated resources.

A revised NMP was needed to:

- Present a formal record of values, aspirations, aims, decisions, and government commitments
- Clearly define the national goals, objectives, and set priorities for the pharmaceutical sector
- Identify the strategies needed to meet those objectives and actors responsible for implementing the main components of the policy
- Create a forum for national discussions on these issues

The hope is that this NMP will:

- Contribute meaningfully to the overall national health policy and the provision of healthcare in the country
- Promote equitable access and availability of quality assured and affordable medicines used rationally and cost effectively with correct information on their usage
- Facilitate the availability of quality pharmaceutical services through the development of the pharmacy profession and pharmaceutical activities
- Facilitate the development of national pharmaceutical industry by providing a clear and stable policy environment
- Facilitate the provision of both governmental and donor funding for medicines.
2. GOAL AND OBJECTIVES

2.1. Goal

The goals of this new edition of the NMP are to ensure the continuous development of the pharmaceutical sector and to meet the health care pharmaceutical requirements of all people living in Afghanistan, through providing and using safe, efficacious, high quality cost-effective and affordable medicines and related products. This policy also serves as the guiding document for legislative reforms, service standardization and resources mobilization, and management for improved quality in the sector. In all respects the policy will be in line with the MoPH’s current strategic planning.4

2.2. Objectives:

The main objectives of NMP 2014 are as below:

- To ensure the availability and accessibility of safe, efficacious, cost-effective, good quality and affordable medicines to the entire population of the country.

- Promote good governance of the pharmaceutical sector, in accordance with accepted ethical and professional standards at all levels.

- Strengthen the quality assurance system to guarantee the safety and efficacy of medicines supplied to clients in both public and private sectors.

- Promote local capacity for the production of essential and complementary medicines.

- Secure sustainable financing and supply of essential and complementary medicines through improved and appropriately documented process of selection, forecasting, procurement, storage, inventory management, and distribution at all levels of the health care system.

- Promote rational medicines use in public and private sectors by improving medicines information, prescription and compliance by the medicines production and, continuous training and research activities.

- Design systems to available and accessible safe, efficacious, high quality, and cost-effective essential complementary, and traditional medicines for rational use in both the public and private sectors.

- Strengthen financing mechanisms to improve sustainability and prudent financial management in the supply of medicines.

- Improve the quantity and quality of human resources for improved pharmaceutical services at all levels of the health system.

- Promote international cooperation and technical assistance for mutual benefit.
3. KEY PRINCIPLES

The NMP is guided by the following principles:

- It is the responsibility of the Government of Afghanistan to ensure equitable access to and rational use of safe, efficacious, high quality, and affordable essential and complementary medicines to all people in Afghanistan, under a sustainable financing system.

- Pharmaceutical services form an essential, critical and integral part of the national health services system.

- There is a need to develop a client-centered pharmaceutical service that recognizes clients’ rights, particularly the right to required information, to enable them to make informed decisions.

4. GOOD GOVERNANCE

The Government of Afghanistan is committed to the Principle of Good Governance as defined by international conventions and national legislation, and is determined to implement governance which is effective, equitable, participatory, accountable, transparent, responsive, and inclusive and follows the Rule of Law.

This National Medicines Policy seeks to ensure that all the principles of Good Governance relating to the Health Sector, as defined in detailed by the World Health Organization Good Governance of Medicines Program, are established and implemented through the pharmaceutical sector in Afghanistan.

In particular:
Extensive research and coordination has been conducted to ensure that this policy follows the existing laws and legislation and their use in Afghanistan.

Further, it enshrines the Good Governance of Medicines principles of:

- Equitability - from access to essential medicines through to affordability of medicines; and applies to all sectors of the pharmaceutical operation in Afghanistan.
- Participation - by promoting the active engagement of all players, public, private, NGOs, donors, UN agencies and partners in pharmaceutical activities.
- Accountability and transparency - through clearly defined responsibilities and open procedures and systems.
- It seeks to be responsive and inclusive - by defining a role for the patients and customers and formalizing complaints procedures and appeals.
5. REGULATION AND QUALITY ASSURANCE

Introduction

Various assessments of Afghanistan’s pharmaceutical sector show that there is little capacity for existing medicines regulation and control for both public and private sectors. Structures, procedures, and policies to regulate the pharmaceutical sector adequately, including provisions for quality assurance, are lacking.

A Medicines Regulatory Authority (MRA) with sufficient capacity, and appropriate medicines information are required to ensure the safety, efficacy, and quality of medicines. All MRA functions must work in concert to provide effective public health protection. Legal structures are the foundation of medicines regulation system.

Since pharmaceuticals frequently are very expensive and therefore prone to production of Substandard/Spurious/Falsely-labeled/ Falsified/Counterfeit medical products medical products (SSFFC). The establishment of viable and sustainable market vigilance through regulatory processes is essential. These processes must be capable of detecting unacceptable products to help provide a deterrent to unscrupulous manufacturers and suppliers.

Objective

To strengthen regulatory and distribution systems that ensure the safety, efficacy, availability, accessibility and affordability of high quality essential and complementary medicines for all people in Afghanistan.

5.1. Regulation

5.1.1. The Government of Afghanistan will remain committed to improving the capacity of medicines regulation to ensure information, availability, safety, efficacy, and quality of medicines in the country.

5.1.2. The Government will further empower the existing National Medicines and Food Board (NMFB) to act as prime policy making body for all medicines matters and the initial monitoring and appealing body for medicines regulatory implementing body.

5.1.3. The government will restructure the GDPA according to the World Health Organization (WHO) recommendations to a fully functional and duly authorized body through appropriate legislation to act as the national medicines regulatory authority (MRA).

5.1.4. The Government will provide the necessary resources to strengthen and maintain the national medicines regulatory capacity.

5.1.5. The Government will provide special incentives to encourage health care providers in the public and private sectors to provide services in remote areas to ensure equitable distribution of pharmaceutical services.
5.1.6. The MRA will:

5.1.6.1. Be an autonomous statutory body accountable to the NMFB and ultimately to the Minister of Public health.
5.1.6.2. Be responsible for the assessment and approval for marketing of all medicines for human use.
5.1.6.3. Set up multidisciplinary expert committees which will be supported by the agenda related departments of MRA
5.1.6.4. Be responsible for supervising all medicines-related activities and the control of medicines.
5.1.6.5. Ensure transparent and efficient medicines registration procedures for the country
5.1.6.6. Have the prerogative to determine which medicines or active ingredients deserve faster processing, subject to public interest
5.1.6.7. Compile and maintain an officially approved medicines register that will be reviewed periodically
5.1.6.8. Determine the classification of premises for the provision of pharmaceutical services in accordance with the therapeutic categories of medicines to be supplied
5.1.6.9. Determine the classification of medicines in accordance with their therapeutic categories and level of distribution in the public interest
5.1.6.10. Be provided with adequate resources, infrastructure, and technical support for strengthening national medicines regulation
5.1.6.11. Maintain one or more inspectorates to monitor all activities in the pharmaceutical sector except for those inspection duties that have been or shall be assigned to other bodies
5.1.6.12. Establish and maintain working links with comparable institutions functioning in other countries or operating on a regional or global basis
5.1.6.13. Assume such other tasks as may be delegated to it by government

5.1.7. Levy fees for the registration and retention of medicines in the medicines register (the fee structure will be reviewed for possible revision periodically).

5.1.8. Use funds generated from medicines registration and licensing for activities to cover part of the Medicines Regulatory Authority operational cost.

5.2. Registration

5.2.1. Only medicines and other pharmaceuticals that are registered in Afghanistan can be supplied to the pharmaceutical markets in the country, unless otherwise approved by the Minister of Public Health in consultation with the National Medicine and Food board.
5.2.2. The criteria for the registration of medicines will be based on the scientific evaluation of quality, efficacy, safety, therapeutic advantage, laboratory testing results, and evidence of Good Manufacturing Practice (GMP).

5.2.3. Registration and marketing authorization of medicines and other pharmaceuticals can only be carried out if the procedures, standards, and facilities for manufacturing of such medicines and other pharmaceuticals have been evaluated and have received prior approval.

5.2.4. A fast-track registration procedure will be established for essential medicines as appropriate for both public and private sectors.

5.2.5. Registration status for each medicines and other pharmaceuticals item will be granted for a period of five years, subject to review and renewal as determined by the MRA.

5.2.6. The national medicines regulatory body will periodically provide and disseminate information to health care professionals and the general public about registered medicines and other pharmaceuticals.

5.2.7. The medicines registration system will be fully computerized and made functional with the appropriate software.

5.2.8. Exchange of information with medicines regulatory authorities of other countries will be strictly on confidential basis.

5.2.9. Internationally acceptable standards will be adopted for the registration of medicines and other pharmaceuticals in Afghanistan.

5.2.10. The manufacture, exportation, importation and distribution of unregistered, counterfeit, substandard, or expired medicines and raw materials will not be permitted and will be punishable by law.

5.3. Control and Inspection

5.3.1. Medicines legislation and regulations will be supported by an adequate and effective system for medicines control and inspection.

5.3.2. The national medicines regulatory body will collaborate and cooperate closely with the relevant statutory bodies, agencies, and health professional bodies.

5.3.3. Psychotropic and narcotic medicines control shall conform to the national laws which are relevant, and the requirements of international substance control treaties which are applicable and to which Afghanistan is a signatory.

5.3.4. A permit system for the manufacturing, importation and exportation of psychotropic and narcotic substances and other under control medicines will be established accordingly.

5.3.5. Only holders of import and export permits who also owns the special permission for export and import of Medicines and medical devices from
MoPH will be allowed to import or export medicines and other pharmaceuticals.

5.3.6. All consignments of medicines and other pharmaceuticals crossing the national borders will be checked against those documents which authorized by MRA.

5.3.7. The national medicines regulatory body or the Ministry of Public Health may allow individuals entering Afghanistan to import limited quantities of medicines prescribed for their personal use as per prescription.

5.3.8. The national MRA will carry out GMP inspections of local pharmaceutical manufacturing plants.

5.3.9. In collaborating with the regulatory agencies of other countries, the national MRA will carry out GMP evaluation of foreign pharmaceutical manufacturing plants.

5.3.10. All premises and vehicles (including carriers by land, air and sea) inside of country, which medicines and other pharmaceuticals are supplied will be subject to inspection.

5.3.11. Pharmacists and any other competent responsible persons may be authorized to perform some defined inspections activities based on TOR after receiving the necessary in-service training.

5.4. Regulation of the Pharmaceutical Profession and Services

5.4.1. As a temporary measure, the registration of pharmacists and the inspection and control of pharmaceutical services will initially be undertaken by the national MRA; when financial and other constraints permit, the registration of pharmacists and pharmacy assistants will be transferred to a Pharmacy Council to be established by law.

5.4.2. Pharmaceutical services serving the public directly will be provided only in duly licensed or authorized health facilities including autonomous state-owned hospitals and in health posts.

5.4.3. Premises for the supply of “prescription only” medicines to the public will be under the direct supervision of qualified pharmacists.

5.4.4. All providers of pharmaceutical services at any level must be registered with the relevant pharmaceutical professional and regulatory bodies in Afghanistan to enable them to practice.

5.4.5. Professional Pharmaceutical services providers, whether trained inside or outside the country who is not duly registered in Afghanistan, their documents will have to be authorized by relevant evaluated body and registered in MRA before they can practice in the country.
5.5. Control of Premises and Providers

5.5.1. All authorized local manufacturers, importers, exporters, and distributors of medicines and other pharmaceuticals must have duly registered premises in Afghanistan.

5.5.2. Wholesalers and retailers of medicines shall procure or obtain medicines and related products only from registered manufacturers, importers, and suppliers in Afghanistan.

5.5.3. All licenses issued for the local manufacture, importation, exportation, and distribution of medicines and other pharmaceuticals will be reviewed and if acceptable renewed, on a fixed periodic basis to be determined by the MRA.

5.5.4. The national medicines regulatory body will develop a comprehensive mechanism for the licensing of premises for the supply of medicines and supervision of services provision in accordance with the level of care and prevailing conditions in the area.

5.5.5. Therapeutic alliances (group practices) between different health care professionals will be encouraged for the purpose of providing cost-effective, high quality health care for the benefit of the general public.

5.6. Specific Quality Assurance Measures

5.6.1. The National Quality Control Laboratory (NQCL) will be upgraded to increase the capacity of service provision at all levels.

5.6.2. Where necessary, the NQCL operations will be supplemented by establishing a series of peripheral laboratories in various regions that capable of performing those forms of quality control which are most frequently required. These small laboratories will be managed and supervised by the NQCL.

5.6.3. A medicines quality assurance system will be developed for the entire medicines supply chain.

5.7. Adverse Reaction Monitoring (Pharmacovigilance)

5.7.1. The National Medicines Information Centre (see section 8.3) will be extended to carry out Pharmacovigilance activities when capacity can be made available.

5.7.2. Practicing physicians, pharmacists and nurses as well as patients will be encouraged to submit to the Centre data on suspected adverse reactions or interactions associated with licensed or traditional medicines.

5.7.3. Local manufacturers, exporters, importers, and distributors of medicines and their authorized representatives in Afghanistan will be required to keep records of all adverse reactions and interactions of medicines reported to them and
submit such reports to the Pharmacovigilance unit of Medicine National Information Centre.

5.7.4. The Medicine National Centre will manage medicines-related data collection, analysis, and the dissemination of relevant information of Pharmacovigilance to the providers and the general public in an efficient manner. The Centre will provide the MRA with monthly reports of its findings, including significant data received from foreign institutions.

5.7.5. The National Pharmacovigilance Centre will establish and maintain close relations, coordination and cooperation with the relevant international medicines and therapeutics information centers and the WHO Collaborating Centre for International Medicines Monitoring in the monitoring and reporting of adverse medicines reactions through the established national pharmacovigilance and medicines information center.

5.7.6. Suppliers of branded medicines will be required to label their product and packages in accordance with the regulations of the MRA which will include with the generic names of the medicines in larger type, and displayed above, the trade name.

5.7.7. The national medicines regulatory body will collaborate closely with other country MRAs, international research institutions, and traditional authorities to identify and investigate complementary medicines.

5.7.8. Efforts will be made for traditional/complementary medicines to be evaluated for safety, efficacy, and quality, and if approved, ultimately be included in the national pharmacopeia.

5.7.9. Mechanisms will be established to regulate internet pharmacy practice Afghanistan based operations as required.
6. LOCAL MANUFACTURE

Introduction

There is currently no pharmaceutical manufacturing plant for active pharmaceutical ingredients in the country, but there are 13 manufacturing plants for finished dosage forms, most privately owned. Afghanistan does not export pharmaceuticals to any degree and does not have a research-based pharmaceutical industry. The bulk of the pharmaceuticals currently in use in Afghanistan are available from foreign producers, many of which offer high quality and dependable production at low cost. The National Medicines Policy is designed to take account of these realities.

Objective

To encourage the local pharmaceutical industry to continuously develop to manufacture high quality essential and complementary medicines needed in Afghanistan and for export.

6.1. Support the Local Manufacturing

6.1.1. The Government will actively encourage local manufacturing companies to produce licensed medicines that are of the same standard of quality and reasonably comparable in terms of cost to the corresponding items from foreign suppliers.

6.1.2. Considering the economic situation of the country it’s better to prefer the manufacture of essential medicines by local manufactures.

6.1.3. Such support may involve a degree of preference in procurement, the provision of training, export incentives or tax relief, or other measures that are acceptable in normal commercial practice, regulation, law, and international agreements. The Government may also promote collaboration with other countries to develop local production, where appropriate, of raw materials or finished products.

6.1.4. In all decisions of Pharmaceutical affairs Priority will be accorded to the local production of items.

6.1.5. The government will support the establishment of industrial parks for local pharmaceutical manufacturing companies.

6.1.6. Government will seek opportunities and develop strategies in order to facilitate the export of pharmaceutical products especially the processed herbal products.

6.1.7. The government is responsible to facilitate communication forum s and any other mechanism between local and external manufacturers, as well as academic centers for experience, knowledge and technology exchanges and export opportunities.
6.2. Traditional Medicines

6.2.1. Having regard to the currently widespread use of herbal and other traditional medicines native to Afghanistan, and the trust placed in these products by the population in general, the Government will accept the continued production, sale, and use of such medicines except where evidence emerges that a particular traditional item is either ineffective or detrimental to health.

6.2.2. At the same time, the Government will promote and encourage research into the properties and usefulness of traditional products so that their rational selection and use are facilitated and, where possible, integrated into general health care and medical practice.

6.2.3. The Government will encourage the sustainable cultivation and harvest of potentially beneficial therapeutic plants for the production of complementary medicines.

6.2.4. In furtherance of this policy, the Government will progressively establish a multi-sectorial mechanism to:

   6.2.4.1. Develop criteria for the selection of complementary medicines for the health system
   6.2.4.2. Screen all potentially beneficial complementary medicines for therapeutic activity, efficacy, safety, and toxicity
   6.2.4.3. Compile a national database of indigenous plants with proven or alleged medicinal value

6.2.5. The national Medicine regulatory authority will introduce a system for the registration of traditional healers, and promote their adherence to a written code of ethics and practice

6.3. Production and Production Inspection

6.3.1. All manufacturing plants—whether producing licensed or tradition medicines—will be required to ensure the safety, efficacy, and quality of medicine by adhering strictly to recognized guidelines for Good Manufacturing Practice (GMP).

6.3.2. Such plants will be inspected regularly by an inspectorate reporting to the national MRA to ensure compliance with GMP guidelines. A list of registered local manufacturing companies and their produced medicines will be compiled, published, and reviewed by the national MRA at least annually.
7. SELECTION

Objective

To ensure that medicines and related products are safe, efficacious, high quality, and affordable, and that available funding is used to the best advantage, it is necessary to set certain priorities.

The first priority must be to ensure that basic lists of essential medicines that meet these criteria are accessible to all and at all times. The World Health Organization (WHO) defines essential medicines as comprising those “that satisfy the needs of the majority of the population.” Every country defines its own list of essential medicines in accordance with the health status and requirements of its population. The list will need to be revised periodically to take account of changing prevalence, new, emerging, or re-emerging diseases and new therapeutic developments.

Beyond this, it will be desirable to make available, a wider range of alternative or supplementary medicines to meet less widespread or less urgent needs (to the extent that the economic situation allows).

7.1. Licensed and Essential Medicines

7.1.1. All medicines that are currently approved and registered for use in Afghanistan and have met the criteria for approval defined in Section 5 will be contained in the Licensed Medicines List (LML).

7.1.2. Within the Licensed Medicines List, the Government, acting through the Minister of Health for preparing requirements of the public sector, will draw up and maintain a more limited list of those items that are considered to meet the WHO criteria for recognition as essential medicines. The Essential Medicines List (EML) will be periodically reviewed and adapted as necessary, in line with Standard Treatment Guidelines and in consultation with all stakeholders.

7.1.3. The selection of medicines for inclusion into the EML will be based on the criteria set by the national medicines regulatory body in order to reflect:

7.1.3.1. The health needs of the majority of the population
7.1.3.2. Availability of sufficient scientific evidence to prove their quality, safety and efficacy
7.1.3.3. Assessment of cost and effectiveness
7.1.3.4. Preference for single pharmacologically active ingredient, except where a fixed dose combination offers a clear therapeutic advantage.

7.1.4. The EML will specify its generic name or International Non-proprietary Name (INN) for each medicine as well as its therapeutic class, dosage forms, and strength, and the level of care at which it can be prescribed in the public sector.
7.1.5. The EML will serve as the principal guideline for the procurement of medicines for use in the public sector, but the Government may extend such procurement to certain additional items where the public health situation renders this necessary.

7.1.6. The LML will also serve as the principal guideline for the development of national medicines formularies, the training of health providers and eligibility for reimbursement under any government-sponsored medical aid or insurance schemes.

7.1.7. The EML will be made available to all health care providers in Afghanistan and any changes made to the EML will be made known through official circulars.

7.1.8. The MRA in consultation with health services provision department of the MoPH will prepare the list of medicines required for different levels of health services and will be circulated for use to all public health facilities after approval by the medicines selection committee.

7.1.9. The EPHS and BPHS health facilities shall prepare their list of required medicines from EML considering the levels and types of services that the facilities provides, the list can be used in the facilities after its approval by the MRA.

7.1.10. The national and specialty hospitals that the EML cannot contain their requirements for their particular specialties; they can prepare a limited list of specialist requirement of product but which must still be contained in the LML and attach the list in their formulary list after such list have received permission of MRA and approval of the selection committee.
8. SUPPLY

Introduction

Access to essential and complementary medicines is a prerequisite for realizing the right to access to health care.\textsuperscript{5} The procurement and supply of medicines should be carried out prudently to ensure that national resources are utilized with care. Stringent management controls need to be implemented to eliminate or reduce wastage in the medicines supply chain system but also to avoid any failure in the supply of medicines.

Objective

To make high quality essential and complementary medicines available in adequate quantities to meet the health needs of the population in all parts of Afghanistan country at the lowest possible cost.

8.1. Procurement

8.1.1. The principles of Good Procurement Practice will be followed in all procurement activities relating to medicines and medical appliances.

8.1.2. The procurement of medicines for the public sector will be limited to medicines in the EML, unless otherwise approved by the Minister for Public Health in consultation with the National Medicine and Food Board.

8.1.3. The procurement of medicines for the private sector will be limited to medicines in the LML, unless otherwise approved by the Minister for Public Health, in consultation with the National Medicine and Food Board.

8.1.4. Procurement will be aimed at securing value for money products of acceptable quality to make the best possible use of available funds.

8.1.5. Procurement of medicines for the public sector will generally be undertaken or supervised/controlled at the national level through national and international competitive tender, performance-based contracting, or other methods in accordance with law.

8.1.6. The evaluation and procurement of essential medicines will be in accordance with WHO certification scheme on the quality of pharmaceutical products moving in international commerce.

8.1.7. Companies registered in Afghanistan will be given preference, provided such preferences are permitted by law regulation and related agreements, in procuring medicines provided that the companies are fully competitive in terms of quality, equal value for money, and reliability of supply.
8.1.8. Government will actively promote efficiency in procurement at all levels by ensuring the involvement of qualified personnel and facilities at all levels, whether operating in the public or private sectors.

8.1.9. Government will establish an autonomous integrated and fully computerized information system for the central and lower supply levels to support procurement.

8.1.10. Market intelligence capability will be developed to improve procurement at the national level.

8.1.11. Procedures will be developed for independent procurement of medicines by autonomous hospitals recognized as nonprofit state-owned enterprises and for the effective monitoring of procurement within these institutes.6

8.1.12. Procurement will be subject to the rules and procedures set out by the Procurement Planning Unit of the Ministry of Finance, 7 except where exemptions may have been granted to meet certain specific needs arising in the health sector.

8.2. Donations

8.2.1. The Government will develop and implement a national Guideline on medicines donation taking into account internationally accepted standards.

8.2.2. The donation of medicines must comply with the above policy.

8.2.3. Donated medicines must meet all of the following criteria:

8.2.3.1. Be certified by the MRA of the exporting country in accordance with the WHO certification scheme on the quality of pharmaceutical products moving in international commerce

8.2.3.2. Be listed in the EML of Afghanistan

8.2.3.3. Have at least 12 months shelf life or (if the normal shelf life is less than 12 months) 75 percent of the remaining shelf life

8.2.3.4. Be labeled in English

8.2.3.5. Be authorized by the Minister for Public Health in consultation with the national medicines regulatory body.

8.3. Storage

8.3.1. Government will seek to ensure the provision and maintenance of adequately sized, suitably constructed, well equipped and secure storage facilities at all levels of the public sector medicines distribution system.

8.3.2. Storage facilities will be subject to inspection based on the recognized standards to ensure their continued adequacy
8.3.3. Regular and periodic checking and monitoring of stored medicines will be performed by the pharmaceutical personnel in charge of the storage facilities at all levels and by inspectors reporting to the MRA.

8.3.4. The Government will ensure that adequate numbers of suitably trained pharmaceutical personnel are recruited to manage public and private sector storage facilities.

8.3.5. Pharmaceutical personnel will be involved in the planning and renovation of medicines storage facilities at all levels.

8.3.6. Deteriorated, obsolete, expired, damaged, banned, and unwholesome medicines will be properly documented and segregated in all warehouses.

8.3.7. Such deteriorated, obsolete, expired, damaged, banned, and unwholesome medicines will be identified and separated from the main medicines, recalled and then disposed of in accordance with national guidelines, under the supervision of the MRA, and in such a way which precludes their use by any person, and with minimal environmental impact.

8.4. Inventory Control and Monitoring of Supply

8.4.1. Computerized ordering, dispensing and inventory control systems will be introduced at all levels, and staff will be trained in their use.

8.4.2. Standard operating procedures will be developed to ensure effective inventory control procedures and accountability at all levels of the public medicines supply system.

8.4.3. Systematic, practical, and accurate procedures for the quantification and regular reporting on medicines consumption will be introduced and maintained to facilitate the national procurement process and expenditures related to monitoring medicines.

8.4.4. The adequacy and appropriateness of medicines supply at all levels shall be regularly monitored in accordance with the standards prescribed in the current edition of the Basic Package of Health Services and Essential Package of Hospital Services.

8.5. Distribution

8.5.1. Medicines shall only be distributed through authorized institutions in the public, parastatal, and private sectors. The Government will develop a common set of standards for all institutions undertaking storage and distribution of medicines.

8.5.2. Multiple distribution mechanism utilizing the resources of the public, private, and NGO sectors will be employed to ensure a reliable supply of essential medicines. In general, the authorized institution providing the medicines will
also undertake the storage and distribution of those medicines. The central medical store will be responsible for managing the distribution of directly government-funded medicines within the public sector; satellite warehouses may be established where necessary to ensure efficient distribution to all parts of the country.

8.5.3. Distribution of medicines will be regularly monitored in the public and private sectors.

8.5.4. Health facilities distributing medicines at any level will keep records of all medicines at the facility at all times.

8.5.5. The Government will facilitate efficient transportation and communication, and provide sufficient personnel to maintain an efficient public sector distribution system.

8.5.6. The Government will promote decentralization of the public sector distribution system as appropriate.

8.5.7. The Government will institute an efficient and practical system for the early identification, collection, and redistribution of excess stocks of medicines and other pharmaceuticals.

8.5.8. The Government will encourage the establishment of special mechanisms for the supply of medicines to underserved communities.

8.5.9. The Government will ensure the creation of facilities for the destruction of expired, illegal, contaminated, or otherwise unwanted medicines in a safe and environmentally acceptable manner.
9. RATIONAL USE OF MEDICINES

Introduction

Rational medicines use (RMU) requires that people receive medicines appropriate to their clinical needs, in doses that meet their individual requirements for an adequate period of time, and at the lowest cost to them and the community, along with the requisite information. Irrational use of medicines may unnecessarily prolong or even cause ill-health and suffering, and result in wastage of limited resources.

The emergence of new and infectious diseases managed with fixed-dose combination medicines and demanding lifelong treatment makes the promotion of adherence to treatment and correct use of medicines crucial. It is therefore imperative to strengthen therapeutic governance to curb the emergence of antimicrobial resistance, medicine abuse, dependence, and tolerance.

Objective

To promote good prescribing and dispensing practices among health care providers as well as informed use of medicines by the community.

9.1. Awareness, Education, Training, and Rational Use of Medicines

9.1.1. All health workers and the general public will be educated on the dangers of irrational use of medicines and medicines abuse.

9.1.2. Stringent educational and regulatory measures will be instituted to minimize the negative effects of medicines advertising and commercial information.

9.1.3. Curricula for all educational programs for health personnel will be revised to incorporate sufficient exposure to the concepts of RMU and related topics.

9.1.4. Health professional bodies will be encouraged to provide mentorship and professional guidance to undergraduates, interns, and colleagues in their respective professions to promote RMU.

9.1.5. Mechanisms will be developed to promote informed use of medicines in the communities and schools.

9.1.6. A team approach to patient care will be encouraged and supported to promote systematic case management in all health facilities in Afghanistan.

9.1.7. RMU indicators will be periodically monitored at the service delivery points throughout the country.

9.1.8. The Minister of Public Health will designate an advisory body to promote RMU by all appropriate means and to monitor progress towards this goal.
9.2. Information

9.2.1. The Government will support, reinforce and equip the functional National Medicines Information Centre with public funding.

9.2.2. The National Medicines Information Centre will:

   9.2.2.1. Periodically produce a medicines information bulletin or newsletter and ensure its distribution throughout the health services and to all relevant stakeholders

   9.2.2.2. Ensure the rapid communication through the media of important new information relating to the safe medicines use

   9.2.2.3. Provide both health workers and the general public on request with specific information relating to medicines

   9.2.2.4. When needed, assist the MRA to obtain information the authority needs for its operations

   9.2.2.5. Promote the unrestricted sharing of medicines information among professional bodies and health care practitioners.

9.2.3. When appropriate and necessary, the Government will ensure the establishment of satellite medicines information and Pharmacovigilance centers throughout the country.

9.3. Rational Prescribing

9.3.1. All medicines, including approved complementary medicines, shall be prescribed by generic or approved names, and in accordance with Good Prescribing Practice.

9.3.2. Mechanisms will be developed to regularly monitor and assess prescribing practices in both the public and private sectors and use the findings to ensure cost-effective and rational prescribing.

9.3.3. The Government will promote the rational prescribing of medicines that have scientifically proven therapeutic efficacy in accordance with the National Standard Treatment Guidelines for the Primary Level of Afghanistan.

9.3.4. The NSTG will be reviewed periodically and disseminated to all health care professionals.

9.3.5. The medicines listed in the national STG will guide the selection of medicines for the EML.

9.3.6. All health care providers directly involved in the diagnosis, prescribing, and dispensing of medicines will be regularly trained on the STG.
9.4. Rational Dispensing

9.4.1. All medicines, including approved complementary medicines, will be dispensed and labeled using generic or approved names and in accordance with Good Dispensing Practice (GDP).

9.4.2. Government will promote the adequate provision of packaging and labeling materials at all dispensaries of public and private health facilities to facilitate GDP.

9.4.3. Government will promote the production of a cross index of generic and proprietary names and facilitate making the information available for all medicines on the Afghanistan market.

9.4.4. Pharmacists in both the public and private sectors will be allowed to substitute identical generic medicines for prescribed branded medicines.

9.4.5. Pharmacists handling prescriptions for branded medicines will, before dispensing such medicines, inform the client about available cheaper generic alternatives.

9.4.6. Prescribers do not allowed to reject those generic medicine which distributed by pharmacist instead of branded medicines.

9.4.7. The MRA will promote the minimum information on the label of a dispensed medicine to be:

9.4.7.1. Name of pharmacy or health facility
9.4.7.2. Date dispensed
9.4.7.3. Name of client
9.4.7.4. Generic name of active ingredient
9.4.7.5. Strength of active ingredient
9.4.7.6. Quantity of medicine dispensed
9.4.7.7. Complete dosage regimen in written or graphic form
9.4.7.8. Prescription number
9.4.7.9. Latest date for use—“use before date”
9.4.7.10. Any relevant special instructions

9.4.8. Dispensing will be performed by pharmacists, pharmacy assistants and by holders of a valid dispensing license.

9.4.9. Premises where dispensing activities are performed will be inspected regularly and in accordance with law to ensure that all legal provisions are being met.
9.4.10. Counseling on the use of medicines, potential side effects, and adherence to therapy will be promoted as part of the dispensing process in all health facilities.

9.4.11. Medicines will not be dispensed based on prescriptions generated via the internet or telephone, except in accordance with approved national guidelines.

9.5. Medicines and Therapeutics Committees

9.5.1. Medicines and Therapeutics Committees (MTC) will be established and made functional at national, provincial, district, and health institution levels for in the public and private sectors.

9.5.2. All MTCs will implement strategies to promote rational, efficient, and cost-effective supply and use of medicines at all health care levels.

9.5.3. MTCs will be responsible for:

9.5.3.1. Assessing medicines and medical supplies requirements for their respective levels
9.5.3.2. Managing and monitoring medicines-related budgets
9.5.3.3. Monitoring compliance with STG and overall medicines utilization
9.5.3.4. Developing appropriate intervention for improved therapeutics
9.5.3.5. Facilitate the provision of relevant and up-to-date medicines use information for prescribers and dispensers
9.5.3.6. Planning for measures to be employed in case of medicine shortage or overstock
9.5.3.7. Developing local formularies and treatment protocols in line with the LML (in Private sector), EML (in Public sector), STG, and MoPH policies
9.5.3.8. Initiating the process of requesting approval for purchasing medicines outside the EML with clear reasons and justifications.
9.5.3.9. Instituting appropriate measures for the prompt, safe and efficient disposal of damaged, deteriorated, expired, or unwholesome medicines
9.5.3.10. Coordinating reports on suspected medicines related adverse events and reporting of such events to the national medicines information and pharmacovigilance center
9.5.3.11. Making recommendations for the inclusion/exclusion of medicines and other pharmaceuticals for the LML and EML
9.6. Anti-microbial Resistance (AMR)

9.6.1. Governing enforces appropriate legislations and guidelines in order to reduce the AMR cases and manage the AMR cases appropriately.

9.6.2. Mechanisms will be developed to effectively monitor and contain antimicrobial resistance, provide access to microbiological laboratories and implementing new interventions

9.6.3. Facilitate the training programs for prescribers and dispensers to educate patients on antimicrobial use and the importance of adherence to prescribed treatments.
10. MEDICINES FOR NEW, EMERGING, AND RE-EMERGING DISEASES

Introduction

Public health concerns continue to be aggravated by challenges presented by new and emerging diseases, while re-emerging diseases such as MDR and XDR TB, also pose new challenges. These diseases become major national issues because their treatment and management usually requires expensive medicines, which may be out of the reach of most people. These medicines are usually new on the global market and constitute a serious financial burden on the Government to make them available to the public.

Objective

To provide safe, quality assured and highly cost-effective medicines for the adequate management and control of new, emerging, and re-emerging diseases.

10.1. Medicines for New, Emerging, and Re-Emerging Diseases

10.1.1. The Government will work to ensure the quality, safety, and rational use of new medicines in both the public and private sectors at all times.

10.1.2. The Government will develop a system to provide essential and complementary medicines for new, emerging, and re-emerging diseases posing challenges for both the public and private sectors.

10.1.3. The Government will collaborate with the relevant international bodies to mobilize resources for new essential medicines to meet national needs.
11. AFFORDABILITY, FINANCING, AND PRICING

Introduction

Financial policies in this field must reflect the need for medicines to be both accessible and affordable for the entire population. For that ideal to be attained and thereafter consistently maintained, financial policies need to be developed at all levels from the procurement of medicines by the health system down to the price paid (by the individual or the health system) when a medicine is delivered to the ultimate user.

It is the MoPH’s responsibility as defined in the National Health Policy and Strategy to ensure stable and adequate financing for health care as a whole despite increasing challenges. The Ministry must also ensure that the financing of medicines supply is fairly shared between the Government and consumers and that stringent price control is maintained and wastage reduced. At all times, the Ministry must ensure that spending is in line with priorities, that there is sufficient transparency in the allocation of financial resources, that the various sources of funding are coordinated, and that the different mechanisms for financing the delivery of health services are monitored for their cost-efficiency and acceptability.

Objective

To mobilize and provide adequate funds for the sustainable supply of essential and medicines to meet national health needs.

11.1. Sustainable Financing

11.1.1. The Government will endeavor at all times to provide adequate funds with long time commitment for the procurement of essential and complementary medicines for all public health institutions.

11.1.2. Since the financial demands posed by the medicines sector unavoidably compete with claims posed by other sectors on the public budget, the MoPH will propose, where feasible, selective cost/benefit studies to document and justify the need for financing in certain areas.

11.1.3. Funds allocated for the supply of medicines will be used efficiently and judiciously in the ultimate interest of the general public.

11.1.4. All possible lawful sources of funding will be explored to generate funds and guarantee adequate supply of essential medicines for all people in Afghanistan.

11.1.5. In development of protocols and treatment methods for the related medicines its alternative should be the most accessible and affordable product

11.1.6. The development of insurance systems, either public or private, to cover medicine costs will be promoted.
11.1.7. The Government will build public-private partnerships to explore and develop alternative financing mechanisms for an efficient pharmaceutical services provision throughout the country.

11.1.8. As much as possible, the Government will make good use of the flexibilities provided for under the World Trade Organization’s trade-related aspects of intellectual property rights (TRIPS) agreement to reduce the financial burden of essential medicines.

11.1.9. Stringent financial control measures will be instituted at all levels of the pharmaceutical services provision to promote efficient use of funds.

11.1.10. Regular and periodic budgeting for pharmaceutical services in accordance with developed guidelines will be enforced to facilitate equitable allocation of funds.

11.1.11. Pharmacists, managers of pharmaceutical services, and other health care providers directly involved in pharmaceutical services in both the public and private sectors will be trained and retrained in financial and data management to promote prudence and efficiency.

11.2. Pricing Structure

11.2.1. In collaboration with the private sector, the Government will develop comprehensive medicines pricing policy aimed at making essential and complementary medicines affordable at all levels and sectors. This will involve both a critical approach to the costs of initial procurement and the imposition of standards regarding the margins earned by manufacturers, importers, wholesalers, and retailers.

11.2.2. The Government will ensure total transparency in the medicines pricing structure, guided by internal and external reference prices.

11.2.3. The Government will critically examine the extent to which existing taxes, tariffs, and duties may impose an avoidable burden on the system (and ultimately on the user) for providing medicines and will propose corrective measures, if necessary.

11.2.4. A system will be established to determine which medicines for curative, preventive, and palliative health services will be provided free of charge at public health facilities.

11.2.5. Patients’ contributions to the cost of treatment and medicines will be in accordance with prevailing national laws and policies.

11.3. Monitoring Prices

11.3.1. A national multi-sectorial system will be developed for monitoring and evaluation of the medicines pricing policy at all levels of the distribution chain.
11.3.2. Accurate data on the pharmaceutical market in Afghanistan, including private household expenditure on medicines, will be compiled and analyzed regularly to determine the effects of the medicines pricing policy and to plan interventions.

11.4. Promoting the Use of Generics

11.4.1. The Government will promote the use of generic names or INN in medicines procurement, distribution, and prescribing, as well as the dissemination of medicines-related information under its generic name at all levels of the health care system.

11.4.2. The Government will promote the use of complementary and alternative multi-sourcing of pharmaceutical products and appropriate incentive packages to reap the advantages of competitive medicines pricing and curtail expenditure.

11.4.3. Health workers, including doctors and pharmacists, will be encouraged to explain to patients the acceptability and cost benefits of generic products. When a product has been prescribed under a brand name, the retail pharmacist will be permitted to dispense a generic equivalent of the same medicine if it is available and prescriber don’t reject the distributed medicines.
12. PHARMACEUTICAL WASTE DISPOSAL

Introduction:

The current volume of medicines used in Afghanistan is low by world standards, and any system of disposal must be firmly in keeping with the realities of current volumes and especially with economic activity levels. World Health Organization Guidelines in conjunction with the Afghanistan Environmental Protection Agency will be used as the guiding base for developing effective disposal policies. As a guiding principle for budgeting purposes one percent of the cost of all medicines to be provided in Afghanistan should be allocated for pharmaceutical product waste management activities. The goal of this section is to protect the health of the public from potential harm which may result from the unsafe or ineffective disposal of expired, damaged or otherwise unwanted medical items including pharmaceuticals.

Objective:

To institute and maintain a system which will ensure the safe, cost effective and controlled disposal or destruction of such items.

12.1. Disposal of expired, damaged, falsified/counterfeit or otherwise unwanted drugs and medical supplies

12.1.1. The GDPA, in cooperation with relevant agencies will be responsible to establish national guidelines for the disposal of these items within the context of an overall national health–care waste management plan.

12.1.2. In accordance with clause 8.5.3.9 of this Policy, the Drug and Therapeutic Committees at all levels will be responsible for the implementation of the national disposal guidelines as they relate to pharmaceutical products.

12.1.3. The national guidelines for disposal of pharmaceutical products will include safe and cost–effective strategies and procedures for:

- Elements to be included in national pharmaceutical training curricula at academic institutions
- Training program for workers handling disposal items
- Identification of drugs and medical supplies waste
- Handling of waste products
- Collection
- Segregation of different product types
- Storage
- Transport
- Disposal/destruction
- Record keeping

12.1.4. GDPA will be responsible to systematically monitor and evaluate the implementation of the drugs and medical supplies waste management plan and make any necessary amendments to the national guidelines.
13. GLOBAL TRADE IN PHARMACEUTICALS AND INTELLECTUAL PROPERTY RIGHTS

Introduction

The TRIPS agreement, a major instrument created by the WTO member states for the health sector, introduces minimum global standards for protecting and enforcing intellectual property rights, including pharmaceutical products and processes. The TRIPS agreement can affect access to medicines required for diseases of public health importance. Governments are obliged have their legislation on intellectual property rights conform to the TRIPS agreement. However, a number of special provisions of the agreement have been adopted to help developing countries comply without due hardship on developing countries.8

Objective

To develop legislation, regulations, and policies that maintain a balance between the minimum standards of intellectual property rights protection and the needs of public health, especially as regarding the supply of essential medicines.

13.1. Development of Appropriate Legislation

13.1.1. The Government will take full advantage of the TRIPS agreement safeguards to promote and maintain public health and to ensure access to essential medicines, while seeking to implement the regulations relating to intellectual property rights.

13.1.2. The Government will actively collaborate with the relevant ministries, agencies, departments, and nongovernmental organizations in the area of intellectual property rights in developing and reviewing the national legal framework that promotes access to essential medicines.
14. ADVERTISING AND PROMOTION

Introduction

Advertising and promoting medicines can be a useful means of disseminating scientific information to health care providers and the community. However, the commercial element inherent in this activity commonly leads to certain unethical and unprofessional practices for the purpose of gaining individuals or a group benefits and which can result in damage to individuals and the community at large. Stringent control measures are necessary to protect the general public.

Objective

To maintain high professional and ethical standards in advertising and promoting essential and complementary medicines to safeguard the general public.

14.1. Responsible Advertising

14.1.1. Government will develop a national policy on the advertising and marketing of medicines, reflecting the sociocultural needs of the country.

14.1.2. Advertising and marketing of medicines shall comply with national policies and with the WHO Ethical Criteria for Medicinal Drug Promotion.

14.1.3. National ethical criteria for medicines promotion and advertising will be established and published periodically for distribution to all interested parties.

14.1.4. All medicines to be advertised or promoted will be registered with the national medicines regulatory body.

14.1.5. All advertisements and promotion of medicines will be of high professional and ethical standards.

14.1.6. Labeling and advertising of medicines will be in conformity with scientifically established evidence, in national languages, and in line with approved package inserts, and culturally acceptable.

14.1.7. Medicines promotional activities will be in line with the NMP objectives.

14.1.8. Whenever the brand name of a medicine is used in any form of promotional or educational material, including electronic and print media advertising, the generic name of the medicine will be given due prominence.

14.1.9. Medicines advertising will always be educational in purpose. Public advertising will be restricted to non-prescription (over-the-counter) medicines only.
14.1.10. When possible and practical, medicines advertising campaigns will be targeted at health professionals rather than the public.

14.1.11. The promotion and advertising of prescription-only medicines will be restricted to professional medical, pharmaceutical, dental, veterinary, or nursing publications.

14.1.12. Inducement of health practitioners with personal financial or material gain in the prescribing and dispensing of medicines will be deemed unethical and unprofessional by all parties involved.

14.1.13. Scientific research results and materials will not be misused to promote medicines.

14.1.14. The national medicines regulatory body will examine and approve all public advertising materials on medicines before they are advertised in print or electronic media.

14.1.15. No advertisement for a medicine will contain a statement which deviates from the evidence submitted in the application for registration where such evidence has been accepted by the national medicines regulatory body.

14.1.16. Using children and women in advertising/promotional media in a socially or culturally unacceptable manner will not be permitted.

14.1.17. Targeting children and women in advertisements for unapproved, unnecessary, untested, or potentially harmful medicines will not be permitted.

14.1.18. Medicine Regulatory Authority will carefully monitor medicines advertising and promotional activities to ensure that they conform to national Scientific, Professional and Ethical standards.

14.1.19. Mechanisms will be developed for members of the public and health professionals to report inappropriate, fraudulent, or illegal medicines advertisements to the national medicines regulatory body.
15. HUMAN RESOURCE DEVELOPMENT AND PHARMACY EDUCATION

Introduction

Sustained human resource development (HRD) of pharmacy is crucial to the attainment of efficient governance and management of pharmaceutical services in particular and health services in general. Robust HRD policies facilitate the right skill mix and optimal utilization of available expertise at all levels. HRD includes the policies and strategies chosen to ensure that there are enough trained and motivated personnel available to implement the components of the NMP.

The Afghanistan National Health Policy and Strategy states that the MoPH is committed to using a comprehensive approach to HRD in addressing the issues of how to produce, deploy, and retain an appropriately trained health workforce possessing the variety of skills needed to deliver affordable and equitable packages of health services as the basis for health care.

Objective

To build the human resource capacity of pharmaceutical services to ensure efficiency, prudent resource utilization, and good therapeutic outcomes.

15.1. Pharmaceutical Human Resource Development

15.1.1. The Government will carry out periodic medium-to-long term needs assessment of pharmaceutical staff at all levels for both public and private sectors, and implement the recommendations emerging from this assessment.

15.1.2. The Government will develop and implement a need based pre-services and in-service programs program to train pharmacists and pharmacy assistants inside and outside the country.

15.1.3. The Government will create an enabling environment for the promotion of pharmacy education and training, especially relating to university level training of graduate pharmacists, and will seek to ensure that the principles of this National Medicine Policy are incorporated into all future pharmacy trainings.

15.1.4. Health professional bodies, academic bodies, tertiary educational institutions, and colleges will be encouraged to include the essential medicines concept, RMU, financial management, and other relevant issues of this policy in the curricula for training health care providers.

15.1.5. A systematic and comprehensive program of in-service training and continuing professional development will be developed and implemented, emphasizing regulation, quality assurance, and pharmaceutical management.
15.1.6. A comprehensive career development structure will be designed for pharmacists and other pharmaceutical services providers to facilitate professional development and motivate staff.

15.1.7. The Government will create the enabling environment for the recruitment and retention of qualified pharmaceutical services providers throughout the country.

15.1.8. Pharmacists and pharmaceutical care providers in rural and underserved areas will be given preference in government bursaries for studies in pharmacy and other related courses.
16. RESEARCH AND DEVELOPMENT

Introduction

Operational research and development (R&D) facilitates the implementation, monitoring, and evaluation of different aspects of the medicines policy. It is an essential tool in assessing the impact of the medicines policy on national health systems and delivery by studying the economics of medicines supply, identifying problems related to prescribing and dispensing, and understanding the sociocultural aspects of medicines use.

According to the National Health Policy and Strategy, the MoPH is committed to encouraging relevant, useful research that can assist evidence-based decision making and the formulation of new policies, strategies, and plans. Nationally led health systems research that is conducted in collaboration with international bodies is a priority.

Objective

To promote operational R&D activities which facilitate the implementation and monitoring and evaluation of the NMP 2013-2018.

16.1. Research and Development in Pharmaceutical Management

16.1.1. Government will promote the development of multidisciplinary operational research and training of research personnel for the relevant areas of pharmaceutical services such as:

16.1.1.1. Impact of the NMP on the national health system and economy
16.1.1.2. Pharmaco-economics of medicine supply and use
16.1.1.3. Prescribing and dispensing practices at different levels of the health system
16.1.1.4. Social and cultural aspects of medicines use vis-à-vis self-medication, acceptability of pharmaceutical services, and attitudes of medicines users

16.2. Technical and Scientific Research

16.2.1. Clinical trials shall only be performed subject to the approval of the national medicines regulatory body in collaboration with relevant technical committee, and shall be in compliance with the WHO Guidelines on Good Clinical Practice.

16.2.2. Exploratory and developmental research into local raw materials and herbal products as sources for new medicines will be encouraged to achieve the objective of increased local production of essential medicines through the promotion of local manufacturing capability.
16.2.3. Government will establish an institute for R&D of medicines. And support the enforcement of it.

16.2.4. Because of limited availability of funds for research, priority will be given to major pharmaceutical challenges in accordance with the goals and objectives of the NMP.

16.2.5. Government will promote the exchange of research findings with other countries and with international agencies.

16.2.6. Government will encourage and support the participation of local researchers and research institutions in international medicines research activities.
17. TECHNICAL COOPERATION

Introduction

Global technical cooperation and assistance constitute a synergistic approach to meeting challenges of diseases of immense public health importance. This provides a platform for exchange various resources when developing pharmaceutical services within the national agenda for health.

The National Health Policy and Strategy promotes effective partnerships and collaboration with all stakeholders sector wide. The MoPH is committed to working in partnership with other stakeholders, and will sustain this through both formal and informal mechanisms.

Objective

To mobilize and optimize resources utilization through the efficient coordination and harmonization of technical cooperation for pharmaceutical systems strengthening, governance, and management.

17.1. Pattern of Technical Cooperation

17.1.1. The Government will strengthen and broaden ongoing bilateral and multilateral technical cooperation and assistance in the national interest.

17.1.2. The Government will establish new links with international organization as appropriate, for national development.

17.1.3. International cooperation and technical assistance will be guided by the findings of monitoring and evaluation activities of the NMP.

17.1.4. The focus of international cooperation and technical assistance will always be on priority areas where high impact can be achieved.

17.1.5. Possible areas of technical cooperation and assistance will include, but are not limited to, the following:

17.1.5.1. Strengthening pharmaceutical systems, governance and management
17.1.5.2. Regulation
17.1.5.3. Quality assurance
17.1.5.4. Development of standard dossiers for essential generic medicines formulations
17.1.5.5. Medicines information and pharmacovigilance
17.1.5.6. Medicines quality surveillance and GMP inspections
17.1.5.7. Improving access to essential medicines
17.1.5.8. Pharmaceutical services human resources development and training
17.1.5.9. Implementation of international narcotic medicines control treaties
17.1.5.10. Containing the emergence of AMR, as well as new and re-emerging diseases
17.1.5.11. R&D in pharmaceutical services and therapeutics
17.1.5.12. R&D in complementary medicines
17.1.5.13. Coordination of response to emergency situations

17.1.6. The guidelines and recommendations of the WHO, United Nations Medicines Control Program, and other relevant international organizations on technical cooperation will be adopted and implemented as appropriate.
18. POLICY IMPLEMENTATION

Introduction

The successful implementation of the NMP 2013-2018 requires a multi-sectorial approach and the full commitment of the Government and all stakeholders. The Government recognizes its pivotal role and shall therefore provide the necessary logistics and funds, and support the MoPH and relevant organizations to fully implement activities derived from this policy.

The policy requires an accompanying national pharmaceutical master plan to make it operational. The master plan will define the various activities, timelines, and resources needed to accomplish the policy statements based on set priorities.

Objective

To make the NMP 2013-2018 implementable in an efficient and prudent manner within an acceptable time frame through the establishment of appropriate systems, structures, and procedures.

18.1. Implementation Plan

18.1.1. A National Pharmaceutical Master Plan (NPMP) will be developed and adopted to facilitate the implementation of this NMP.

18.1.2. The NPMP will define priority areas and outline short-to-medium-to-long term action plans with defined activities, budgets, time frames, responsibilities, and expected outcomes and outputs, as appropriate.

18.1.3. The NPMP will take into consideration experiences and lessons learned from the implementation of the previous policy and all activities carried out in the pharmaceutical sector.

18.1.4. The national medicines regulatory body (which is the well-developed form of current GDP), will lead the coordination and implementation of this NMP and its accompanying NPMP.

18.1.5. Government will facilitate the smooth implementation of this NMP.
19. MONITORING AND EVALUATION

Introduction

An effective monitoring and evaluation (M&E) program system facilitates objective data and information gathering for reporting progress and resource mobilization. Furthermore, M&E provide useful feedback information for objective assessment and informed management decisions.

Key issues include monitoring of the pharmaceutical sector through regular indicator-based surveys, and independent external evaluation of the policy’s impact on all sectors of the national economy. Systematic and regular monitoring provides the platform for continuous review that shows how planned activities are being implemented and indicates how targets are being met.

The National Health Policy and Strategy promotes mechanisms to ensure the availability, coordination, distribution, and use of accurate, reliable, user-friendly health information in the design, implementation, and monitoring and evaluation of health services and other related activities.

Objective

To develop a yearly M&E plan that will facilitate the assessment of performance in the implementation of the NMP 2013-2018 in accordance with set out strategies, objectives, and activities in the pharmaceutical master plan.

19.1. Mechanisms of Monitoring and Evaluation

19.1.1. A comprehensive M&E system clearly stating the sector-wide indicators will be developed to periodically assess the performance of this NMP for informed management interventions.

19.1.2. The efficiency and effectiveness of the policy will be evaluated periodically, and strategies and activities will be adjusted as necessary.

19.1.3. The Government will use the findings of M&E as a guide to setting priorities, to strengthen those strategies that will have the best impact, to synchronize policy, and to determine future areas of international cooperation and technical assistance.

19.1.4. The national medicines regulatory body (currently GDPA) will lead the M&E of the NMP and its accompanying NPMP.
GLOSSARY

**Active pharmaceutical ingredient:** A substance or compound that is intended to be used in the manufacture of a pharmaceutical product as a therapeutically active compound (ingredient).

**Adverse medicines reaction (adverse drug reaction):** A response to a pharmaceutical product which is harmful and unintended and that occurs at doses normally used or tested in humans for prophylaxis, diagnosis, or treatment of disease, or for the modification of physiological function.

**Agreement on Trade-related Aspects of Intellectual Property Rights:** An international agreement administered by the World Trade Organization (WTO) that sets down minimum standards for many forms of intellectual property regulation as applied to nationals of other WTO Members, with the goal "to promote access to medicines for all."

**Basic package of health services:** Standardized basic services that provide the core of service delivery in all primary health care facilities.

**Counterfeit medicine:** A medicine which is deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients, or with fake packaging.

**Efficacy:** The ability of a medicine, whether a modern medicine or traditional, to treat or control a disease.

**Essential medicines list:** A list of medicines approved for use in public sector health facilities.

**Essential medicines:** Medicines that satisfy the priority health care needs of the population.

**Essential package of hospital services:** The necessary elements of service mix, staff, facilities, equipment, medicines, and consumables for each type of hospital at each level which satisfying the public health needs through hospital services provision

**Ethical criteria for medicinal promotion:** Criteria prepared by an international group of experts to give manufacturers, distributors, the promotion industry, prescribers, and consumer groups a framework to ensure that promotional practices are in keeping with acceptable ethical standards.

**Excipient:** A substance or compound other than the active pharmaceutical ingredient and packaging materials that is intended or designated to be used in the manufacture of a pharmaceutical product.

**Fast-track registration procedure:** A system to prioritize and expedite the processing of applications for registration of pharmaceutical products.

**National Food and Medicines Board:** The NMFB is a body to advise, coordinate, oversee and accelerate medicines and food-related activities, and implement basic principles on the affairs related to the regulation of pharmaceuticals, medical devices, cosmetics, sanitation
equipment and traditional pharmaceuticals (medicines) to ensure their safety, quality, efficacy and effectiveness, as well as to ensure the safety and quality of food products and prevent their unnecessary and unsafe manufacture, importation, distribution, sale and use.

**Generic name:** A unique name identifying a particular pharmaceutical substance. Generic names are officially assigned by international medicines nomenclature commissions and nowadays mostly conform to those assigned by the WHO program on the selection of INN.

**Generic products:** Products marketed under a non-proprietary or generic name rather than a proprietary or brand name, often at a cheaper price.

**Good clinical practice:** A standard for clinical studies which encompasses the design, conduct, monitoring, termination, audit, analyses, reporting and documentation of the studies, and which ensures that the studies are scientifically and ethically sound, and that the clinical properties of the pharmaceutical product under investigation are properly documented.

**Good distribution practice:** Is good and standard practices for activities related to Distribution of Medicine, which is as part of quality assurance, ensure the preservation and sustainability of medicine products quality during its distribution.

**Good manufacturing practices:** Is good and standard practices for activities related to manufacturing of Medicine, which is as part of a pharmaceutical quality assurance system ensures that products are consistently manufactured and produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.

**Good pharmaceutical procurement practice:** A rigorously documented, monitored, audited system and procedures, for ensuring transparent and accountable procurement practices and appropriate quality assurance mechanisms providing for the provision of the specified quantities at the specified quality at the specified time in the specified place at the lowest evaluated price.

**Good pharmacy practice:** The supply of medication and other health care products, of assured quality, appropriate information and advice for the patient, and monitoring the effects of their use.

**Good storage practice:** Documented system and procedures for receiving, arranging, storing and transporting pharmaceuticals so as to maintain the quality of the products throughout the handling processes.

**Good trade and distribution practices:** Part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.

**Government:** The Islamic Republic of Afghanistan.

**Health management information system:** Used for collecting routine information on key basic package of health services, keeping the registration of facilities with unique identification numbers; and supporting data base management.

**Health practitioner and professional:** One who is fully licensed and approved by the relevant national authorities to practice medicine or an allied health profession such as
nursing, pharmacy, radiography on humans.

**Interchangeable multisource pharmaceutical products:** Pharmaceutical products from different manufacturers with the same active ingredient and in the same dosage form, which have the same therapeutic effect as the reference product.

**International non-proprietary name:** The shortened scientific name (also known as the generic name) of a pharmaceutical substance assigned by the WHO program on the selection of INNs. The INN is recognized worldwide.

**Licensed medicines list:** All medicines that are approved for use in Afghanistan at different levels of the health system

**Licensing authority:** General name for any statutory body delegated by the Government to register health practitioners and to regulate their professional practice.

**National Medicines regulatory authority:** An entity/organization/structure in charge of the administration of the medicines regulation, including at least one of the following regulatory activities:

- Issuing marketing authorization of new products and dealing with variation of existing products;
- Testing the Quality of products;
- Monitoring adverse drug reaction and events;
- Inspecting and licensing of manufacturers, wholesalers and distribution channels and related enforcement operations;
- Controlling medicines promotion and advertisement
- Providing of medicines information and promotion of rational use of medicines and:
- Other tasks relevant to pharmaceutical.

**Narcotic:** Are natural or chemical compounds which will cause an abnormal changes in the function of central nervous systems and consciousness level also will create increasingly psychological and physiological dependency or addiction for the humans, in its consequences cause adverse effect on physical, mental and social performance.

**Over the counter medicines:** Medicines that are generally regarded as safe for the consumer for use by following the required label directions and warnings, which may be purchased without a prescription.

**Pharmaceutical product:** Any medicine, medicinal product, herbal medicine, and any substance included in any publication mentioned in the Medicines Laws or any substance or mixture of substances prepared, sold or represented for use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state, or symptoms thereof, or restoring, correcting or modifying organic functions in man.

**Pharmaceutical sector:** The sector of health care concerned with the knowledge or art of pharmacy and its practice according to specific rules and formulas.

**Pharmacist:** An individual who is fully licensed and approved by the relevant national
authorities to practice pharmacy in Afghanistan.

**Pharmacopoeia:** A publication issued by an authorized national or international commission which specifies quality standards and other properties of pharmaceutical substances and dosage forms.

**Pharmacovigilance:** The science of detection, assessment and prevention of adverse reactions and related problems, as a major resource for ensuring the safe and rational use of medicines.

**Prescription only medicines:** Medicines that can only be made available to the consumer through a written order signed by a duly qualified and registered medical prescriber and dispensed by a registered pharmacist.

**Prescription:** A written instruction signed by a registered and authorized healthcare practitioner to dispense specified medicines in specified quantities to a named patient.

**Procurement:** All management activities required for providing sufficient health products of assured quality, procured at the lowest price and in accordance with national and international laws to the end user in a reliable and timely fashion.

**Product recall:** A process for withdrawing or removing a pharmaceutical product from the pharmaceutical distribution chain because of defects in the product or complaints of serious adverse reactions to the product.

**Program medicines:** Medicines used in public health programs of the Ministry of Public Health, within the guidelines of the specific programs.

**Psychotropic:** Are chemical compounds which will cause abnormal changes in the nervous systems functions and alter the physical, sense and behavior which continuously using it will cause addiction and in case of stopping its use adverse effects will be observed.

**Public health:** The prevention of disease, improving life and promoting health through organized efforts of society related to populations/communities as opposed to individuals.

**Quality assurance:** An integrated and complete system which includes the appropriate infrastructure, organizational structure, procedures, processes, resources, and systematic actions necessary to ensure adequate confidence that an organizational entity will satisfy the given requirements for pharmaceutical product quality.

**Quality control:** An integrated and complete process which documents all measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that raw materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.

**Quality management:** The degree of excellence of a service or a system in meeting the health needs of those most in need at the lowest cost, and within limits, directives, or regulations.

**Rational medicines use:** Patients receive medicines appropriate for their clinical needs in doses that meet their individual requirements for adequate period of time, and at the lowest cost to them and their community.
Registration of medicines: The process of registering medicines to be allowed to be sold on the market, and includes evaluation of safety, efficacy, and quality of the pharmaceutical product.

Therapeutic advantage: A significant improvement of efficacy or safety of one pharmaceutical product over another of the same therapeutic class seen in daily practice.

Therapeutic alliances: The cooperation of health workers with different qualifications in a private practice to increase accessibility to and quality of services provided.

Traditional medicine: is a material or product of plant, animal and mineral origin that is used in traditional practices in order to protect the health and to treat disease which its effectiveness is proven by traditional medicine reliable sources.
REFERENCES


9[http://www.whocep.org/research/Glossary%20of%20Terms.pdf](http://www.whocep.org/research/Glossary%20of%20Terms.pdf)

10GDPA / Avicenna Pharmaceutical Institute